Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 166

1.

Comparative in vitro susceptibility of besifloxacin and seven comparators against ciprofloxacin- and methicillin-susceptible/nonsusceptible staphylococci.

Miller D, Chang JS, Flynn HW, Alfonso EC.

J Ocul Pharmacol Ther. 2013 Apr;29(3):339-44. doi: 10.1089/jop.2012.0081. Epub 2013 Jan 4.

PMID:
23289847
2.

Ocular pharmacokinetics/pharmacodynamics of besifloxacin, moxifloxacin, and gatifloxacin following topical administration to pigmented rabbits.

Proksch JW, Ward KW.

J Ocul Pharmacol Ther. 2010 Oct;26(5):449-58. doi: 10.1089/jop.2010.0054.

PMID:
20874668
3.

Penetration and effectiveness of prophylactic fluoroquinolones in experimental methicillin-sensitive or methicillin-resistant Staphylococcus aureus anterior chamber infections.

Balzli CL, Caballero AR, Tang A, Weeks AC, O'Callaghan RJ.

J Cataract Refract Surg. 2010 Dec;36(12):2160-7. doi: 10.1016/j.jcrs.2010.06.070.

PMID:
21111321
4.

Antibiotic Resistance in the Treatment of Staphylococcus aureus Keratitis: a 20-Year Review.

Chang VS, Dhaliwal DK, Raju L, Kowalski RP.

Cornea. 2015 Jun;34(6):698-703. doi: 10.1097/ICO.0000000000000431. Review.

5.

Efficacy of besifloxacin in a rabbit model of methicillin-resistant Staphylococcus aureus keratitis.

Sanders ME, Norcross EW, Moore QC 3rd, Shafiee A, Marquart ME.

Cornea. 2009 Oct;28(9):1055-60. doi: 10.1097/ICO.0b013e31819e34cb.

PMID:
19724203
6.

Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae.

Haas W, Pillar CM, Hesje CK, Sanfilippo CM, Morris TW.

J Antimicrob Chemother. 2010 Jul;65(7):1441-7. doi: 10.1093/jac/dkq127. Epub 2010 Apr 30.

7.

Ciprofloxacin and levofloxacin resistance among methicillin-sensitive Staphylococcus aureus isolates from keratitis and conjunctivitis.

Marangon FB, Miller D, Muallem MS, Romano AC, Alfonso EC.

Am J Ophthalmol. 2004 Mar;137(3):453-8.

PMID:
15013867
8.

Efficacy of besifloxacin in an early treatment model of methicillin-resistant Staphylococcus aureus keratitis.

Sanders ME, Moore QC 3rd, Norcross EW, Shafiee A, Marquart ME.

J Ocul Pharmacol Ther. 2010 Apr;26(2):193-8. doi: 10.1089/jop.2009.0121.

PMID:
20334537
9.

In vitro efficacy and pharmacodynamic indices for antibiotics against coagulase-negative staphylococcus endophthalmitis isolates.

Harper T, Miller D, Flynn HW Jr.

Ophthalmology. 2007 May;114(5):871-5. Epub 2007 Mar 26.

PMID:
17383732
10.

Topical fluoroquinolone use as a risk factor for in vitro fluoroquinolone resistance in ocular cultures.

Fintelmann RE, Hoskins EN, Lietman TM, Keenan JD, Gaynor BD, Cevallos V, Acharya NR.

Arch Ophthalmol. 2011 Apr;129(4):399-402. doi: 10.1001/archophthalmol.2011.45.

11.

Antibiotic susceptibility of staphylococci isolates from patients with chronic conjunctivitis: including associated factors and clinical evaluation.

Blanco C, Núñez MX.

J Ocul Pharmacol Ther. 2013 Nov;29(9):803-8. doi: 10.1089/jop.2013.0040. Epub 2013 Aug 14.

12.

In vitro activity of fluoroquinolones against ocular bacterial isolates in São Paulo, Brazil.

Oliveira AD, D'Azevedo PA, Francisco W.

Cornea. 2007 Feb;26(2):194-8.

PMID:
17251812
13.

Emerging 8-methoxyfluoroquinolone resistance among methicillin-susceptible Staphylococcus epidermidis isolates recovered from patients with endophthalmitis.

Bispo PJ, Alfonso EC, Flynn HW, Miller D.

J Clin Microbiol. 2013 Sep;51(9):2959-63. doi: 10.1128/JCM.00846-13. Epub 2013 Jul 3.

14.

[Resistance profiles to fluoroquinolones in clinical isolates of Gram positive cocci].

Hidalgo M, Reyes J, Cárdenas AM, Díaz L, Rincón S, Vanegas N, Díaz PL, Castañeda E, Arias CA.

Biomedica. 2008 Jun;28(2):284-94. Spanish. Erratum in: Biomedica. 2008 Sep;28(3):460.

15.

Dichotomous selection of high-level oxacillin resistance in Staphylococcus aureus by fluoroquinolones.

Dalhoff A, Schubert S.

Int J Antimicrob Agents. 2010 Sep;36(3):216-21. doi: 10.1016/j.ijantimicag.2010.04.014. Epub 2010 Jul 14.

PMID:
20630710
16.

[Comparative activity of daptomycin against clinical isolates of methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci].

Picazo JJ, Betriu C, Rodríguez-Avial I, Culebras E, López F, Gómez M; Grupo VIRA..

Enferm Infecc Microbiol Clin. 2010 Jan;28(1):13-6. doi: 10.1016/j.eimc.2008.09.012. Epub 2009 May 5. Spanish.

PMID:
19406529
17.

Antistaphylococcal activities of the new fluoroquinolone JNJ-Q2.

Morrow BJ, Abbanat D, Baum EZ, Crespo-Carbone SM, Davies TA, He W, Shang W, Queenan AM, Lynch AS.

Antimicrob Agents Chemother. 2011 Dec;55(12):5512-21. doi: 10.1128/AAC.00470-11. Epub 2011 Sep 12.

18.

Fluoroquinolone susceptibilities to methicillin-resistant and susceptible coagulase-negative Staphylococcus isolated from eye infection.

Oliveira AD, Höfling-Lima AL, Belfort R Jr, Gayoso Mde F, Francisco W.

Arq Bras Oftalmol. 2007 Mar-Apr;70(2):286-9.

19.

Comparison of besifloxacin, gatifloxacin, and moxifloxacin against strains of pseudomonas aeruginosa with different quinolone susceptibility patterns in a rabbit model of keratitis.

Sanders ME, Moore QC 3rd, Norcross EW, Sanfilippo CM, Hesje CK, Shafiee A, Marquart ME.

Cornea. 2011 Jan;30(1):83-90. doi: 10.1097/ICO.0b013e3181e2f0f3.

PMID:
20847656
20.

Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureus and Escherichia coli.

Cambau E, Matrat S, Pan XS, Roth Dit Bettoni R, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM.

J Antimicrob Chemother. 2009 Mar;63(3):443-50. doi: 10.1093/jac/dkn528. Epub 2009 Jan 15.

PMID:
19147516

Supplemental Content

Support Center